MAPT and Alzheimer disease: There is much interest in whether GSK-3β inhibitors can be used as a therapeutic tool for AD, because of the link between GSK-3β activity and tau phosphorylation (Hooper et al., 2008; Muñoz-Montaño et al., 1997).